Optimizing Care for Infantile Hemangioma:: Scope and Referral Considerations for Pediatricians

Infantile hemangiomas (IHS) are the most common benign vascular tumors of infancy, affecting up to ۱۰% of children. They typically follow a predictable course of rapid proliferation in early infancy, followed by slow involution during childhood. While most IHS are small, superficial, and self-limiting, approximately ۱۰% carry risks of ulceration, functional impairment, disfigurement, or even life-threatening complications. General pediatricians are well positioned to identify IHs during routine examinations, particularly at the six-week check, and play a central role in initial diagnosis, risk stratification, and parental education. Most IHS can be diagnosed clinically. Imaging is reserved for specific scenarios: ultrasound with Doppler helps assess atypical or deep lesions and rule out visceral involvement, while MRI is used for extensive segmental lesions or when syndromic associations such as PHACE or LUMBAR are suspected. Biopsy is rarely necessary but may help clarify uncertain cases. Low-risk IHS can be safely managed in primary care with observation, reassurance, and structured follow-up. Families should be educated on the natural history of IHs, advised to document lesion changes with photographs, and alerted to signs of rapid growth or complications. "Watchful waiting" remains appropriate for uncomplicated lesions, but vigilance is essential to identify those requiring active treatment. When intervention is needed, oral propranolol remains the gold standard. Administered at ۲-۳ mg/kg/day in divided doses, it is most effective when started in the proliferative phase (ideally by ۱-۵ months of age) and continued for at least six months. Propranolol has a clearance rate approaching ۹۵% and works through vasoconstriction, inhibition of angiogenesis, and induction of endothelial apoptosis. Adverse effects include sleep disturbance, hypoglycemia, bronchospasm, and rare rebound growth after cessation. Caregivers should be advised to administer doses with feeds and to monitor for side effects. Topical timolol may be considered for small, superficial lesions. Corticosteroids, pulsed-dye or Nd:YAG laser, and surgery are second-line options, reserved for refractory or complicated cases. Red-flag features, such as ulceration, bleeding, airway compromise, visual threat, or signs of cardiac or endocrine dysfunction, warrant prompt referral to specialists, including dermatology, cardiology, ophthalmology, or otolaryngology. Segmental, periorbital, perioral, or multiple cutaneous lesions also require early evaluation for systemic involvement. In summary, while the majority of IHS can be monitored in primary care, pediatricians must remain alert to high-risk features. Timely recognition and referral ensure optimal outcomes and minimize long-term complications.